Boston Scientific Shares Fall on Watchman Usage Slowdown
Boston Scientific Shares Fall on Watchman Usage Slowdown
Boston Scientific (BSX) shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device Watchman. CEO Michael Mahoney said at Bernstein's annual conference that the company has seen a declining usage of Watchman stand-alone procedures in 2026.
Changing Treatment Patterns
Mahoney noted that doctors are increasingly combining Watchman procedures with other heart treatments during a single visit, rather than performing it as a standalone procedure. Watchman is a small implant placed in the heart to prevent blood clots and strokes, especially in patients with atrial fibrillation who cannot take long-term blood thinners.
Growth Expectations
The company expects flat dollar growth from the first quarter to the second quarter, and likely in the third quarter. Boston Scientific maintained its full-year organic revenue growth forecast of 6.5% to 8%, a range it had previously narrowed from higher expectations. Analysts say the update pushes off a recovery in investor trust.
Impacted Symbols
Symbols affected by this headline and their sentiment signals
The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.
More Headlines
Tokyo Core Inflation Slows, Remains Below BOJ Target
Tokyo Core Inflation Slows, Remains Below BOJ Target
…Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
Nikkei May Rise on Hopes for U.S.-Iran Peace Deal
…Australian Pension Fund HUB24 Faces Regulatory Scrutiny
Australian Pension Fund HUB24 Faces Regulatory Scrutiny
…